GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of targeted therapies known as GO-203-2C and
bortezomib as a possible treatment for multiple myeloma that has either progressed or not
responded to treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Genus Oncology, LLC National Institutes of Health (NIH)